Large prospective study to evaluate a non-invasive prenatal screening test
Application backed by landmark phase 3 data validating MRD-guided treatment in bladder cancer
ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera™ in organ rejection
New publication shows that Prospera-guided care helped >75% of low-risk patients safely avoid routine transbronchial biopsies performed at 9 months
2 Cash-Producing Stocks to Consider Right Now and 1 Facing Headwinds
Study reports high sensitivity and specificity, enabling MolDX submission and path to reimbursement in CRC
EXPAND clinical trial to be presented; data support Fetal Focus™ sgNIPT for inherited conditions
New AI-derived model integrates longitudinal ctDNA and clinical data with digital pathology and tumor sequencing data, to refine recurrence risk assessment and outcomes prediction
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a new collaboration with NVIDIA to accelerate the development of Natera’s multimodal...
2025 revenues are expected to increase by approximately 35% compared to 2024, which is approximately $40 million above the top end of Natera’s financial outlook Additional...